Patanjali Faces Licence Suspension for 14 Products Following Supreme Court Reproach

Patanjali, the renowned Ayurvedic products manufacturer, finds itself in hot water as the licensing authority in Uttarakhand has swiftly moved to suspend the licences of 14 of its products. This action comes in the wake of an affidavit filed by the licensing body in the Supreme Court, detailing the suspension of licences for these products manufactured by Patanjali’s Divya Pharmacy. The suspension is directly linked to a case involving misleading advertisements.

The products affected by the licence suspension include several well-known offerings from Divya Pharmacy, such as Drishti Eye drop, Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh, Mukta Vati Extra Power, Lipidom, Bp Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, and Eyegrit Gold.

The Supreme Court is scheduled to address the matter pertaining to the apology published by Yoga guru Ramdev and his associate Acharya Balkrishna on April 30, with both individuals expected to be present in court on Tuesday.

In the previous hearing on April 23, the Supreme Court reprimanded Patanjali for what it perceived as insufficient prominence given to their published apology in newspapers. The court queried whether the size of the apology matched the full-page advertisements typically used for Patanjali’s products. Patanjali responded by highlighting its publication of apologies in 67 newspapers, affirming its profound respect for the court and its commitment to rectifying mistakes.

Following the court’s directive, Patanjali published a subsequent apology in newspapers, which notably exceeded the size of the previous one.

Before these developments, Ramdev and Balkrishna had tendered an “unconditional and unqualified apology” to the top court regarding advertisements issued by Patanjali, which made ambitious claims about the efficacy of its products like Coronil during the pandemic.

The Supreme Court had previously instructed Patanjali to cease advertisements of products claiming to treat specific ailments and disorders outlined in the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. This directive came during the hearing of a plea filed by the Indian Medical Association (IMA) seeking action against Ramdev for disparaging modern medicine.

Source Link

 If you like this law news, share it with a friend!